COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
REPLY: The Board of Directors approved the draft financial statements for the year 2024
Reply S.p.A. Board of Directors approves draft financial statements for 2024, proposing dividend distribution of €1.15 per share. Positive financial indicators with increased turnover and net profit -
COMMUNIQUÉ DE PRESSE
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses
Xenetic Biosciences presents promising findings on combining DNase I with CAR T cells to enhance cancer treatment strategies at the SITC Spring Scientific 2025 Cell Therapy Meeting -
COMMUNIQUÉ DE PRESSE
Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform
Aspire Biopharma Holdings, Inc. provides update on patent applications for Oral Mucosal Formulations of Aspirin with rapid absorption technology. Company aims to revolutionize drug delivery and improve patient outcomes -
-
-
COMMUNIQUÉ DE PRESSE
Prince Holding Group Earns Fifth Consecutive ‘Best in Cambodia’ Award for CSR Initiatives
Prince Holding Group recognized as 'Best in Country Excellence - Best in Cambodia' at the 17th Annual Global CSR & ESG Awards for sustainable development efforts. Awards highlight ongoing CSR and ESG initiatives guided by Chairman Chen Zhi -
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain
MIRA Pharmaceuticals introduces topical Ketamir-2 for neuropathic and inflammatory pain, expanding pain management portfolio with innovative targeted approach -
